Do GLP-1 Medications Affect Heart Health?

GLP-1 medications have become treatments discussed in recent years not only for blood sugar control or weight management, but also for their effects on cardiovascular health. Especially risks such as type 2 diabetes, obesity, insulin resistance, hypertension, high cholesterol and abdominal fat can directly affect heart health. Therefore, when GLP-1 treatment is evaluated, the person’s overall cardiometabolic profile should definitely be addressed together.

The effect of GLP-1 medications on heart health is not the same in everyone. The molecule used, treatment purpose, existing cardiovascular disease history, diabetes status, weight level, blood pressure and cholesterol values can affect the outcome. The World Health Organization states that some GLP-1 medications can reduce the risk of heart attack, stroke and heart failure, and may also have effects on outcomes such as type 2 diabetes, kidney and liver disease.

What Is GLP-1 And How Is It Related To Heart Health?

GLP-1 is a natural hormone secreted from the intestines that helps regulate the metabolic response after meals. This hormone supports insulin release, reduces the effect of glucagon, the hormone that raises blood sugar, slows gastric emptying and contributes to increased satiety. GLP-1 receptor agonists are medications that mimic the effects of this natural hormone.

The importance of GLP-1 treatment for heart health is not limited only to direct effects on the heart. Improved blood sugar control, weight loss, reduced waist circumference, lower inflammatory burden, and possible positive changes in blood pressure and lipid values may affect cardiovascular risk. Therefore, GLP-1 treatment is evaluated in an area where metabolic health and cardiovascular health intersect.

Can GLP-1 Medications Reduce The Risk Of Heart Attack And Stroke?

There is strong clinical evidence that some GLP-1 treatments can reduce the risk of serious events such as heart attack, stroke and cardiovascular death in certain patient groups. Especially in people with type 2 diabetes and high cardiovascular risk, some GLP-1 receptor agonists are among important options in treatment guidelines because of their cardiometabolic benefits.

This topic has also become important for people without diabetes but with obesity or excess weight and existing cardiovascular disease. In March 2024, the FDA approved semaglutide for use in reducing the risk of serious heart problems in adults with cardiovascular disease and obesity or excess weight. This approval shows that GLP-1 treatments can be evaluated not only for weight loss but also for cardiovascular risk in specific groups.

Which Outcomes Are Monitored For Cardiovascular Risk?

Looking only at weight loss is not enough to evaluate cardiovascular health during GLP-1 treatment. The person’s general risk profile should be monitored with different measurements.

• Blood Sugar Control: Fasting blood sugar, post-meal blood sugar and HbA1c values are important in diabetes and cardiometabolic risk follow-up.
• Blood Pressure Values: Hypertension is an important risk factor for cardiovascular diseases and should be monitored regularly during treatment.
• Lipid Profile: LDL, HDL, total cholesterol and triglyceride values should be evaluated for vascular health.
• Waist Circumference: Abdominal fat is closely related to metabolic syndrome and cardiovascular risk.
• Kidney Functions: Diabetes, hypertension and obesity can affect kidney health; kidney status should be addressed together with cardiovascular risk.
• Speed Of Weight Loss: Very rapid weight loss should be monitored for nutritional insufficiency and muscle loss.

Is GLP-1 Treatment Suitable For Every Heart Patient?

GLP-1 treatment may benefit some people with high cardiovascular risk; however, this does not mean the medication is automatically suitable for every heart patient. When making a treatment decision in someone with heart disease, current diagnoses, medications used, kidney functions, blood pressure level, history of rhythm disorder and diabetes status should be evaluated together.

More careful follow-up is needed especially in people with heart failure, severe kidney disease, multiple medication use, advanced age, tendency to dehydration or intense gastrointestinal side effects. Knowing existing risks in terms of heart health before starting GLP-1 treatment helps plan the treatment more safely and personally.

Do GLP-1 Medications Affect Blood Pressure?

During GLP-1 treatment, some people may experience changes in blood pressure values together with weight loss, changes in nutrition routine and metabolic improvement. Weight loss and improvement in insulin resistance may positively affect blood pressure. However, this effect varies from person to person and should not always be expected at the same level.

People using blood pressure medication should be monitored for symptoms such as dizziness, fatigue or low blood pressure during GLP-1 treatment. The person should not reduce or stop blood pressure medication on their own. Blood pressure values should be monitored regularly, and if medication adjustment is needed, it should be done by a physician.

Do GLP-1 Medications Affect Cholesterol And Triglyceride Values?

During GLP-1 treatment, weight loss, changes in eating habits and improved blood sugar control may affect the lipid profile. In some people, improvement may be seen in triglyceride, total cholesterol or LDL values. However, this result should not be considered only medication-related; nutrition, exercise, genetic structure and existing metabolic diseases are also decisive.

Cholesterol and triglyceride values are important indicators of cardiovascular health. Monitoring these values at baseline and during follow-up in people using GLP-1 helps understand the overall cardiometabolic effect of treatment. Lipid follow-up should not be neglected especially if there is a family history of early heart disease, diabetes, hypertension or fatty liver.

GLP-1 And Heart Health In People With Type 2 Diabetes

Type 2 diabetes is an important risk factor for cardiovascular diseases. High blood sugar can affect vascular health, kidney functions, the nervous system and cardiovascular structure over time. Therefore, the goal in diabetes treatment is not only to lower blood sugar, but also to reduce cardiovascular risk.

Some GLP-1 receptor agonists may be especially considered in the treatment plan of people with type 2 diabetes and high cardiovascular risk. The standards of the American Diabetes Association emphasize that cardiovascular, kidney, weight and metabolic risks should be regularly addressed in diabetes care.

Values That Can Be Monitored For Heart Health In Type 2 Diabetes

When GLP-1 treatment is planned in people with diabetes, different health indicators other than blood sugar are also important.

• HbA1c: Shows the average blood sugar level over the last 2-3 months and helps evaluate treatment response.
• Fasting And Post-Meal Blood Sugar: Provides information about daily glucose control.
• LDL Cholesterol: It is one of the main risk indicators for vascular health.
• Blood Pressure: Blood pressure control in people with diabetes is critical for heart and kidney health.
• eGFR And Creatinine: Help monitor kidney functions.
• Urine Albumin: May contribute to noticing the early effects of diabetes on the kidneys.

Can GLP-1 Be Used For Heart Health In People Without Diabetes?

In people without diabetes, GLP-1 treatment is not an approach suitable for everyone only to support heart health. However, in some people with obesity or excess weight together with existing cardiovascular disease, certain GLP-1 treatments can be evaluated for cardiovascular risk reduction. This decision must be made by a physician.

At this point, the distinction between medical necessity and aesthetic use is important. Starting GLP-1 treatment only to lose weight quickly, look thinner or because it is popular on social media is not appropriate. If a benefit is expected in terms of heart health, the person’s current diagnoses, risk factors and suitability for treatment should be clearly evaluated.

Can GLP-1 Treatment Affect Heart Rate?

During GLP-1 treatment, a mild increase in heart rate may be seen in some people. This may not be noticeable in every person and often may not create a clinical problem by itself. However, these symptoms should be taken seriously in people with palpitations, chest pain, shortness of breath, fainting sensation or a history of rhythm disorder.

Heart rate changes may not be related only to the medication. Dehydration, inadequate nutrition, low blood sugar, excessive caffeine consumption, stress, sleep disorder or accompanying heart diseases may also increase the feeling of palpitations. Therefore, if new palpitations or chest discomfort occur while using GLP-1, medical evaluation should be obtained.

How Does Rapid Weight Loss During GLP-1 Treatment Affect Heart Health?

Weight loss with GLP-1 treatment may progress quickly in some people. Reduction of excess weight can be positive for cardiovascular health; however, very rapid and uncontrolled weight loss is not always ideal. Insufficient protein intake, muscle loss, dehydration, electrolyte imbalances and fatigue can negatively affect the treatment process.

Preserving muscle mass is important for metabolic rate and long-term weight management. Therefore, while using GLP-1, nutrition plan, exercise routine and blood values should be followed together. For heart health, not only the decrease on the scale but also body composition and general energy status should be considered.

Which Tests Can Be Followed For Heart Health While Using GLP-1?

The tests to monitor heart health during GLP-1 treatment vary according to the person’s risk status. The same tests do not need to be done for everyone. However, regular follow-up is more important especially if there is diabetes, hypertension, high cholesterol, history of heart disease or obesity.

At baseline, blood sugar, HbA1c, lipid profile, kidney and liver functions should be evaluated. When necessary, ECG, blood pressure monitoring, waist circumference measurement, urine albumin and cardiology evaluation can also be planned. Which test should be done and how often should be determined according to the person’s treatment goals and risks.

Controls That Can Be Evaluated For Heart Health

These controls help monitor the cardiometabolic effects of GLP-1 treatment more holistically.

• HbA1c And Blood Sugar: Followed in terms of diabetes, prediabetes and insulin resistance.
• Lipid Profile: LDL, HDL, total cholesterol and triglyceride values are evaluated.
• Blood Pressure Measurement: Hypertension risk or current blood pressure treatment is monitored.
• ECG: Can be planned if there is palpitation, chest pain or history of rhythm disorder.
• Kidney Functions: Creatinine, eGFR and urine albumin level may be evaluated.
• Liver Enzymes: May be monitored for fatty liver and metabolic risk.
• Waist Circumference And Weight Follow-Up: Practical indicators of cardiometabolic risk.

Why Is Nutrition Important For Heart Health While Using GLP-1?

GLP-1 treatment may reduce appetite and portions. However, this does not mean that the person is eating adequately and in a balanced way. To support heart health, protein, fiber, healthy fats, vegetables, whole grains and adequate fluid intake should be planned in a balanced way.

An extremely low-calorie, unbalanced or one-type diet may increase muscle loss, fatigue and metabolic strain. In terms of heart health, saturated fat, excess sugar, processed foods and high salt intake should also be limited. In GLP-1 treatment, the nutrition plan is important not only for losing weight but also for protecting vascular health and metabolic balance.

Does Exercise Support Heart Health While Using GLP-1?

Regular exercise is one of the key areas that supports heart health during GLP-1 treatment. Walking, resistance exercises, low-intensity cardio, stretching and a personalized movement plan may contribute to weight management, preservation of muscle mass and improved insulin sensitivity.

The exercise plan should be arranged according to age, fitness level, heart disease history, joint health and treatment side effects. If chest pain, shortness of breath, fainting sensation, intense palpitations or severe fatigue occurs, exercise should be stopped and evaluation should be obtained. People with heart disease should create their exercise plan with physician guidance.

Who Should Be Followed More Closely During GLP-1 Treatment?

Some people may need more frequent follow-up during GLP-1 treatment. A more careful follow-up plan should be created especially in people with a history of cardiovascular disease, diabetes, hypertension, kidney disease, fatty liver, gallbladder problems, history of pancreatitis or multiple medication use.

Advanced age, rapid weight loss, intense gastrointestinal side effects, reduced fluid intake, palpitations or blood pressure changes may also require close monitoring. New symptoms that develop during treatment should not be dismissed as “normal side effects”; their duration and severity should be considered.

People Who May Require Close Follow-Up

In these groups, the effects of GLP-1 treatment on the heart and metabolism should be evaluated more carefully.

• People With Cardiovascular Disease: History of heart attack, stroke, vascular occlusion or heart failure is important.
• People With Type 2 Diabetes: Blood sugar and cardiometabolic risks should be monitored together.
• People With Hypertension: Blood pressure values and medication routine should be followed.
• People With High Cholesterol: Lipid profile should be checked regularly.
• People With Kidney Disease: Dehydration and kidney functions require attention.
• People Using Multiple Medications: Medication interactions and dose adjustments should be evaluated by a physician.

Is Unconscious Use Of GLP-1 Medications Risky For Heart Health?

The popularization of GLP-1 medications has increased the risk of uncontrolled use. Searching for non-prescribed products, counterfeit medications, dose increases influenced by social media or starting treatment without physician follow-up can lead to serious health problems. This is also risky for heart health.

Unconscious use may cause dehydration, electrolyte imbalance, blood sugar fluctuations, palpitations, blood pressure changes and overlooking underlying diseases. Especially in people with cardiovascular disease, GLP-1 treatment must be planned with medical evaluation and regular follow-up.

General Evaluation For GLP-1 And Heart Health

GLP-1 medications may provide positive effects on blood sugar, weight and cardiometabolic risks in some people. Certain treatments are also evaluated for reducing the risk of cardiovascular events in suitable patient groups. However, these results are not the same for everyone and treatment should be planned personally.

The most accurate approach for heart health is to consider GLP-1 treatment as part of a comprehensive metabolic health plan rather than seeing it as a standalone solution. When nutrition, exercise, blood values, blood pressure, lipid profile, kidney functions and existing diseases are monitored together, the process can progress more safely and sustainably.

Happ Health Online Endocrinologist Support

If you want to evaluate whether GLP-1 medications are suitable for your heart health, blood sugar values, weight management or metabolic risks, you can access online endocrinologist support through Happ Health. Endocrinology evaluation helps address GLP-1 treatment together with diabetes, obesity, insulin resistance, thyroid functions and cardiometabolic risks.

Happ Health, as a digital health platform, offers a solution that provides access to healthcare services from home or remotely. Through the online health application, you can share your current tests, medications, cardiovascular risks and health history with a specialist and plan your GLP-1 treatment process more consciously, safely and according to your personal needs.